Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $66,495.00 in Stock

Key Points

• Enliven Therapeutics' CFO, Benjamin Hohl, sold 3,250 shares at an average price of $20.46, reducing his stake by 12.38% to 23,000 shares valued at approximately $470,580.
• The company's stock is currently priced at approximately $19.32 with a market cap of $948.03 million, and analysts have set a consensus price target of $41.20 for the stock.
• In recent analyst reports, Goldman Sachs initiated coverage on Enliven Therapeutics with a "buy" rating and a target price of $37, while HC Wainwright raised its target to $48.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $20.46, for a total value of $66,495.00. Following the completion of the sale, the chief financial officer directly owned 23,000 shares in the company, valued at $470,580. This represents a 12.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, July 10th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.66, for a total value of $22,660.00.
• On Friday, June 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.91, for a total value of $67,957.50.
• On Tuesday, May 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.18, for a total value of $52,585.00.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock traded down $0.08 during mid-day trading on Friday, hitting $18.73. 490,125 shares of the stock were exchanged, compared to its average volume of 376,154. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03. The company has a 50-day simple moving average of $20.68 and a 200 day simple moving average of $20.12. The company has a market capitalization of $919.08 million, a P/E ratio of -9.76 and a beta of 0.93.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). Analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ELVN. Tower Research Capital LLC TRC grew its position in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after purchasing an additional 1,114 shares in the last quarter. GAMMA Investing LLC grew its position in Enliven Therapeutics by 3,058.1% in the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock worth $53,000 after acquiring an additional 2,630 shares in the last quarter. Quantbot Technologies LP purchased a new position in Enliven Therapeutics in the first quarter worth $60,000. KLP Kapitalforvaltning AS purchased a new position in Enliven Therapeutics in the fourth quarter worth $97,000. Finally, BNP Paribas Financial Markets purchased a new position in Enliven Therapeutics in the fourth quarter worth $112,000. Institutional investors own 95.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ELVN. HC Wainwright boosted their price target on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Jones Trading decreased their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. The Goldman Sachs Group assumed coverage on Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 price target for the company. Finally, Robert W. Baird boosted their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, June 16th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.